지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.6
- 수록면
- 15 - 18 (4page)
이용수
초록· 키워드
오류제보하기
Purpose: Bevacizumab has been used as a promising drug for metastatic colorectal cancer in combination with chemotherapeutic agents. However, it has a few serious adverse effects, such as intestinal bleeding or perforation. The purpose of this study is to identify the clinical characteristics of intestinal perforation induced by bevacizumab in colorectal cancer patients.
Methods: From January 2007 to June 2018, a total of 488 patients underwent chemotherapy with bevacizumab for metastatic colorectal cancer. Medical records were reviewed retrospectively.
Results: Nine patients (1.8%) were identified with intestinal perforation induced with bevacizumab. The median age was 59 years (range, 36–68 years). The primary tumor site was the sigmoid colon in six patients, the rectum in three patients. The liver was the most common metastatic organ (7 patients). Perforation sites were primary tumor site of the colorectum in four patients and the small bowel in five patients. Intestinal perforation was developed after a median of 3 chemotherapy cycles (range, 1–15 cycles), and a median of 7 days (range, 3–32 days) after chemotherapy. One patient expired due to sepsis.
Conclusion: Bevacizumab induced intestinal perforation is a lethal adverse effect in patients with colorectal cancers. The characteristics of intestinal perforation varied according to perforation site, previous chemotherapy cycles, and clinical course. Careful monitoring is necessary with the use of bevacizumab in conjunction with chemotherapeutic agents.
Methods: From January 2007 to June 2018, a total of 488 patients underwent chemotherapy with bevacizumab for metastatic colorectal cancer. Medical records were reviewed retrospectively.
Results: Nine patients (1.8%) were identified with intestinal perforation induced with bevacizumab. The median age was 59 years (range, 36–68 years). The primary tumor site was the sigmoid colon in six patients, the rectum in three patients. The liver was the most common metastatic organ (7 patients). Perforation sites were primary tumor site of the colorectum in four patients and the small bowel in five patients. Intestinal perforation was developed after a median of 3 chemotherapy cycles (range, 1–15 cycles), and a median of 7 days (range, 3–32 days) after chemotherapy. One patient expired due to sepsis.
Conclusion: Bevacizumab induced intestinal perforation is a lethal adverse effect in patients with colorectal cancers. The characteristics of intestinal perforation varied according to perforation site, previous chemotherapy cycles, and clinical course. Careful monitoring is necessary with the use of bevacizumab in conjunction with chemotherapeutic agents.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (10)
참고문헌 신청
Presta LG / 1997 / Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders / Cancer Res 57:4593~4599
Kabbinavar F / 2003 / Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer / J Clin Oncol 21:60~65
Giantonio BJ / 2007 / Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 / J Clin Oncol 25:1539~1544
Hurwitz H / 2004 / Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer / N Engl J Med 350:2335~2342
Scappaticci FA / 2005 / Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab / J Surg Oncol 91:173~180
Kabbinavar F / 2003 / Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer / J Clin Oncol 21:60~65
Giantonio BJ / 2007 / Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 / J Clin Oncol 25:1539~1544
Hurwitz H / 2004 / Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer / N Engl J Med 350:2335~2342
Scappaticci FA / 2005 / Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab / J Surg Oncol 91:173~180
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Bevacizumab Induced Intestinal Perforation in Metastatic Colorectal Cancers
대한외과학회 학술대회 초록집
2018 .11
-
Comparison of gastric and other bowel perforations in preterm infants: a review of 20 years' experience in a single institution
Korean journal of pediatrics
2015 .01
-
Rectal perforation by compressed air
Annals of Surgical Treatment and Research
2017 .07
-
Endoscopic and Clinical Factors Affecting the Prognosis of Colorectal Endoscopic Submucosal Dissection-Related Perforation
Gut and Liver
2016 .01
-
Delayed Perforation Occurring after Gastric Endoscopic Submucosal Dissection: Clinical Features and Management Strategy
Gut and Liver
2024 .01
-
Prediction of Intestinal Perforation in Very Low Birth Weight Infants Using Machine Learning
대한외과학회 학술대회 초록집
2021 .11
-
Management of gastrointestinal tract perforations
International Journal of Gastrointestinal Intervention
2017 .10
-
Long-term Clinical Outcomes and Risk of Peritoneal Seeding after Endoscopic Submucosal Dissection for Early Gastric Cancer: A Focus on Perforation during the Procedure
Gut and Liver
2019 .01
-
Clinical implication of spontaneous gastrointestinal perforation in pediatric patients : its difference according to age group
Annals of Surgical Treatment and Research
2018 .09
-
Unexpected Delayed Colon Perforation after the Endoscopic Submucosal Dissection with Snaring of a Laterally Spreading Tumor
Clinical Endoscopy
2015 .01
-
Esophageal perforation in children: etiology and management, with special reference to endoscopic esophageal perforation
Korean journal of pediatrics
2018 .01
-
Perforation on the Superior Side of Duodenum Is a Risk Factor of Laparoscopic Primary Repair for Duodenal Ulcer Perforation
대한외과학회 학술대회 초록집
2021 .05
-
Experience of serious intestinal hemorrhage and perforation in small bowel lymphoma: a case report
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2021 .12
-
Perforation on the superior side of duodenum is a risk factor of laparoscopic primary repair for duodenal ulcer perforation
Annals of Surgical Treatment and Research
2021 .04
-
Gallbladder perforation : a single center experience of 32 cases
Annals of Hepato-Biliary-Pancreatic Surgery
2015 .02
-
Multiple small bowel perforation caused by intestinal involvement of miliary tuberculosis
대한외과학회 학술대회 초록집
2017 .11
-
Perforated Choledochal Cyst: Its Clinical Implications in Pediatric Patient
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
End or And...근관치료시 천공의 수복
대한치과의사협회지
2017 .08
-
Meaningful standard of reference for appendiceal perforation : pathology, surgery, or both?
Annals of Surgical Treatment and Research
2017 .08
-
식도 천공의 치료 및 임상적 분석
대한이비인후-두경부외과학회지
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0